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orphan drugs (ODs). This study examined the characteristics of
OD designations and approvals in the U.S. and in the EU cen-
tralized system between August 1, 2000 and December 31, 2007
and compared the characteristics of sponsors, products and indi-
cations. METHODS: Data derived from the US FDA and the
European Medicines Agency (EMEA). Chi-Square and Fishers’
exact tests, and group comparison t-tests were used in the analy-
sis. RESULTS: In the study period, the FDA listed 773 orphan
designations and 65 (8.4%) approvals, and the EMEA listed 492
designations and 37 (7.5%) approvals. Orphan designations
were granted to 472 sponsors by the FDA and to 293 sponsors by
the EMEA. The sponsors included 30 universities, public orga-
nizations and individual sponsors in the U.S. and 20 in the EU.
The average OD designations per sponsor were 1.64  1.63 in
the U.S. and 1.68  1.51 in the EU. 68.9% of sponsors in the
U.S. and 65.9% of sponsors in the EU had only 1 OD designa-
tion. The time from OD designation to approval was
1.74  1.45 years in the FDA and 2.73  1.43 years in the
EMEA (p < 0.001). 98 (14.7%) sponsors had OD designations in
both agencies. There were 102 designations in both agencies that
had the same sponsor, product and indication; and 76 designa-
tions that had the same product and indication and different
sponsor. CONCLUSIONS: US had more designations and
approvals, but the analysis excludes ODs approved by national
European agencies. OD incentives encourage R&D by small
sponsors that, otherwise, could not assume the risk and oppor-
tunity cost associated with developing such products. The imple-
mentation of the FDA/EMEA common OD application in
November 26, 2007 aims to reduce the duplication in OD devel-
opment found in this study.
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OBJECTIVES: This study aimed to identify the most important
factors affecting the total cost and the length of stay (LOS) of
neonates who were hospitalized in six neonatal intensive care
units (NICUs) in Greece. METHODS: The study sample con-
sisted of 218 neonates who entered the NICUs of six maternity,
pediatric and general hospitals, of Greece. Multivariate Regres-
sion analysis was performed in order to examine the factors
affecting the LOS and the total cost of hospitalization. Data on
mother and father educational and occupational status, type and
number of delivery, place of residence (rural or urban), age of the
mother, birth weight and the gestational age of the infants were
available. The costs used for the analysis, emerged from a
detailed cost analysis, bottom up approach, based on daily con-
sumption of each neonate for the whole period of hospitaliza-
tion, until discharge of the hospital. Bootstrap simulation was
used with 1000 iterations in order to check for the stability of the
cost analysis. RESULTS: Factors inﬂuencing the LOS (in days)
and the total cost (in Euro) were identical in both regression
models. Factors for LOS were the type of the hospital, since in
the pediatrics hospitals neonates stayed longer than in the
maternity hospitals (coefﬁcient 17.44; 95%CI 4.61 to 30.28,
p = 0.004) and the birth weight of the neonate (coefﬁcient 25.03;
95%CI: 8.304 to 41.77, p = 0.004). Factors for the total cost
were the length of stay (coefﬁcient 228.11; 95%CI: 218.53 to
237.68, p < 0.001), the type of the hospital (coefﬁcient 993.72;
95%CI 301.03 to 1686.42, p = 0.005) and birth weight of the
infant (coefﬁcient 1528.07; 95%CI 700.61 to 2355.54,
p < 0.001). CONCLUSIONS: The ﬁndings, as expected, proved
that the lower the birth weight, the more prolonged and more
costly the hospitalization. Differences in the type and organiza-
tion between hospitals need further attention.
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OBJECTIVES: Anxiety is frequently associated with major
depressive disorder (MDD). Antidepressants are approved for
MDD and some anxiety disorders. However, few data exist on
real-life utilisation and outcomes of antidepressant treatments in
patients with MDD and co-morbid anxiety. This study aims
at describing and comparing treatment patterns, health care
resource use and associated costs in these patients. METHODS:
This cohort study using the US claims database PharMetrics
included adults with a ﬁrst prescription of an antidepressant
(escitalopram, an SSRI or venlafaxine) associated with a diagno-
sis of MDD in 2003–2005, and with two diagnoses of anxiety in
the year surrounding this ﬁrst prescription. Treatment patterns,
health care resource use and related costs were assessed during
the 6-month before and after ﬁrst prescription, and compared
across treatment groups. RESULTS: Of 18,676 patients, 69%
were women, and mean age was 40. 25% of patients were
prescribed escitalopram, 64% SSRIs, and 11% venlafaxine.
Treatment patterns showed a 15% switch rate, a 16% combina-
tion rate and 23% of stops with no subsequent relapse (success-
ful treatment stop). Both switch and combination rates were
lower with escitalopram vs. SSRIs and venlafaxine (p < 0.001
and p = 0.002 respectively). Successful treatment stops were
more frequent with escitalopram vs. venlafaxine (p < 0.001).
6-month total health care costs after treatment initiation were
not signiﬁcantly different than before (US$ 4,656 vs. US$4,254),
but the structure of costs differed, with more pharmacy costs
(20% vs. 10%), and less inpatient care (36% vs. 51%) after
treatment start. Compared with baseline costs, health care costs
were decreased with escitalopram and increased with SSRIs and
venlafaxine (-US$74 vs. + US$496 and + US$916 respectively).
CONCLUSIONS: In patients with MDD and co-morbid anxiety,
antidepressant treatment was generally associated with decreased
inpatient care. Compared with SSRIs and venlafaxine, escitalo-
pram was associated with less treatment changes and with
decreased costs.
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OBJECTIVES: This study was designed to investigate the impact
of medicaid expansion on preventable hospitalization(PH) trend.
METHODS: Data from the Korea National Health Insuran-
ce(NHI) claims andmedicaid claims database, covering 48million
Korean people, was used. The new medicaid people were selected
who were enrolled ﬁrst time during the medicaid expansion
period, the year 1998–1999. The NHI enrollees were randomly
selected for control group. All were continuously enrolled from
1996 to 2001 and aged more than 17 years. Multinomial logit
regressionmodels of comparing PHversusmarker admissionwere
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estimated. Model variables included insurer’s type, age, gender,
charlson comorbidity index, year. Odd ratios(OR) and 95%
conﬁdence intervals(CI) were used to investigate the impact of
medicaid expansion on PH trend. The PHwas deﬁned as a class of
admission believed to be preventable in most cases by standard
ambulatory health care before admission. The marker admissions
were determined such as appendicitis and gastrointestinal
obstruction, remaining relatively constant across populations.
RESULTS: Among newly enrolled 140,366 medicaid population,
62.1% were female, mean age was 52 years old. These percentage
of female and mean age among 280,301 NHI population were
53.1% and 39 years old, respectively. The biennial ratio of PH
relative to marker admission in medicaid population increased
after eligibility expansion, from an average of 6.05 to
9.04(OR = 1.50). This rise was small compared with the NHI
populations, who experienced from 1.96 to 3.22(OR = 1.64).
After adjusting for confounding variables, the OR for after med-
icaid expansion among medicaid population and NHI population
were 1.48(95% CI = 1.29–1.69) and 1.71(95% CI = 1.53–1.91),
respectively. CONCLUSIONS: Current ﬁndings suggest that the
medicaid PH trend was less likely to rise than NHI PH trend after
implementing medicaid expansion.
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OBJECTIVES: The purpose of this study is to examine the
impact of visual acuity (VA) on bilateral neovascular age-related
macular degeneration (nvAMD) patients’ general quality of life
(QOL). Instead of the traditional correlation/linear regression
analysis, a novel approach using PROBIT regression on cumula-
tive QOL rates was employed. METHODS: Data from a
cross-sectional, multi-country (France, Germany, Spain, UK and
Canada) burden of nvAMD was examined (n = 401 nvAMD
patients). As part of the telephone interview, patients completed
EQ-5D as the assessment of general quality of life (QOL). Asso-
ciations between VA and EQ-5D were examined using traditional
Pearson correlation, analysis of variance (ANOVA) test of
EQ-5D score as a function of VA level (normal, mild, moderate,
severe, and near blindness), and PROBIT regression. In the
PROBIT regression, the decimal VA was ordinalized into catego-
ries centered at 0.02, 0.04, 0.06, etc., and cumulative QOL rates
were calculated at each of these levels. RESULTS: Pearson cor-
relation and one-way analysis of variance tests showed no sig-
niﬁcant association between VA and EQ-5D. From the PROBIT
regression, the inﬂection points were determined and the mean
and standard deviation of the underlying normal distribution
were estimated. The inﬂection points identify the VA levels at
which association between QOL and VA may be expected and at
what level no association would occur. The mean and SD dem-
onstrate where the relationship was linear. While the Pearson
correlation showed a 0.01 correlation coefﬁcient between EQ-5D
and VA, PROBIT regression showed a 0.89 correlation coefﬁ-
cient, with the association being linear between VA range of 0.02
and 0.40. CONCLUSIONS: The association of VA levels and
EQ-5D is affected by many extraneous variables that make it
difﬁcult to identify the strength of the association. The use of
PROBIT regression gives researchers an important methodologi-
cal tool to strengthen their understanding of such associations.
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OBJECTIVES: When a budget impact analysis is performed for
the introduction of a new drug, the diffusion of the drug needs to
be forecasted. Such forecast should be as evidence-based as pos-
sible if it is to be useful for health care decision makers. We
assessed the usefulness of several models for predicting the diffu-
sion of new drugs on the Dutch market. METHODS: Several
diffusion models were assessed, and the most useful in the context
of a new drug entering the market was selected. Next, historical
diffusion was analysed based on Farminform and IMS data. This
data provides sales (volume) at the level of the active substance for
the total Dutch market each month. Data was available from
January 1993 until October 2006. We included data on 22
products divided over 6 ATC 2 categories (ATC = Anatomical
Therapeutic Chemical). RESULTS: We found that the Hahn
model is most applicable for new drugs. The Hahn model was
capable of describing diffusion retrospectively of the 22 drugs
studied. The results provide insight in the diffusion pattern which
can be used to forecast diffusion of new interventions. Based on
these empirically derived descriptors of diffusion some ﬁndings
were: The biggest growth (relative to the previous period) of a
product is achieved between roughly 12 and 36 months; No
products are observed with a market (ATC2) penetration of more
than 45%; In less than a ﬁfth of the introductions, a market share
ofmore than 20%at theATC2 level is achievedwithin 60months;
In less than a tenth of the introductions, a market share of more
than 35% at the ATC 2 level is achieved within 60 months.
CONCLUSIONS: The assumptions about market diffusions cur-
rently made in budget impact analyses can be greatly improved if
formal models are used to predict diffusion.
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OBJECTIVES: Most international pharmacoeconomic guide-
lines advise not to include future unrelated medical costs in
economic evaluations. Recently, arguments in favor of inclusion
of such costs are gaining support in health economic literature.
However, correct estimations of these costs do not yet exist. This
paper describes the methodology with which we developed a
toolkit to adjust incremental cost-effectiveness ratios (ICER) for
future unrelated medical costs, and presents an application of the
toolkit by adjusting the ICER of universal hepatitis B vaccination
of newborns. METHODS: We deﬁned three variables that
predict individual health care expenditure best: age, sex and time
to death. However, the relation between health care expenditure
and these three variables depends on the lethality of diseases and
on health care setting. For the development of the toolkit, differ-
ent cross-sectional and longitudinal databases were used. First,
the 2003 Dutch Cost of Illness study has been employed. Fur-
thermore, insurance claims data and longitudinal record linkage
data were used. This allowed us to estimate how the relation
between time to death and health care costs is altered if costs of
related diseases are excluded. To apply the toolkit, survivor
curves for the intervention and control groups are needed. For
hepatitis B vaccination of newborns, future unrelated medical
costs (i.e. all costs not related to hepatitis B infection and
Abstracts A361
